Resume of Ban CHEN

Basic Information



School: School of Life and Health Sciences

Gender: Male
Date of Birth: 199507
Title: Lecturer

Education: Doctor of Medicine
Tutor: Master's Degree

Interest of Computer Aided Drug Design; research: Pharmacodynamic Substances and

Quality Standards of Traditional

Chinese Medicines

Academic Background

From September 2017 to June 2022, Guangzhou University of Chinese Medicine, Doctor of Medicine.

From September 2013 to June 2017, Hubei University of Chinese Medicine, Bachelor of Engineering.

Enrollment Information

1. Enrollment Discipline: Master of Pharmacy

2. Research direction: Computer Aided Drug Design

3. Enrollment Year: 2024-2025

Representative Projects

- 1. Hubei Provincial Natural Science Foundation of China (2023AFB373), Project leader.
- 2. National Natural Science Foundation of China (82304707), Project leader.
- 3. Doctoral Research Initiation Grant of Hubei University of Technology (XJ2022004001), Project leader.

Representative Articles

- [1] CHEN B, LI X, LIU J, et al. Antioxidant and Cytoprotective effects of *Pyrola decorata* H. Andres and its five phenolic components[J/OL]. BMC Complementary and Alternative Medicine, 2019, 19(1): 275. DOI:10.1186/s12906-019-2698-y.
- [2] CHEN B, LI X, LIU J, et al. Ferroptosis-Inhibitory Effect and Possible Mechanisms of Ellagitannin Geraniin[J/OL]. ChemistryOpen, 2021, 10(8): 737-739. DOI:10.1002/open.202000255.

- [3] CHEN B, LI X, OUYANG X, et al. Comparison of Ferroptosis-Inhibitory Mechanisms between Ferrostatin-1 and Dietary Stilbenes (Piceatannol and Astringin)[J/OL]. Molecules, 2021, 26(4): 1092.
- [4] CHEN B, LIU S, LI X, et al. Reconstruction of quality marker system for *Ginkgo Folium* tablet using UHPLC-Q-Orbitrap MS, quantum chemical calculation, network pharmacology, and molecular simulation[J]. Phytochemical Analysis. 2024;1–15.
- [5] CHEN B, LIU S, LI X, et al. Database-aided ultrahigh-performance liquid chromatography Q-Exactive-Orbitrap tandem mass spectrometry putatively identifies 16 unexpected compounds and three anticounterfeiting pharmacopoeia quality markers for *Perillae Fructus*[J/OL]. Rapid Communications in Mass Spectrometry, 2024, 38(13): e9762.
- [6] CHEN B, OUYANG X, CHENG C, et al. Bioactive peptides derived from *Radix Angelicae sinensis* inhibit ferroptosis in HT22 cells through direct Keap1–Nrf2 PPI inhibition[J/OL]. RSC Advances, 2023, 13(32): 22148-22157.
- [7] CHEN B, SU J, HU Y, et al. Antioxidant mechanisms and products of four 4',5,7-trihydroxyflavonoids with different structural types[J/OL]. RSC Medicinal Chemistry, 2022, 14(1): 173-182.
- [8] CHEN X, HUANG Y, CHEN B, et al. Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges[J/OL]. European Journal of Medicinal Chemistry, 2023: 115947.
- [9] LI X, OUYANG X, CHEN B, et al. Linkage and Stereochemistry Characters of Phenolic Antioxidant Product Formation[J/OL]. Journal of Agricultural and Food Chemistry, 2023[2023-02-06]. https://doi.org/10.1021/acs.jafc.2c06563.
- [10] SU J, LI D, HU Y, et al. A novel C6-sulfonated celastrol analog as a tyrosinase and melanin inhibitor: Design, synthesis, biological evaluation and molecular simulation[J/OL]. Journal of Molecular Structure, 2023, 1283: 135288.